Key Biotec News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Press release content from Accesswire. The AP news staff was not involved in its creation. Key Capital Strengthens Vaccine Patents February 18, 2021 GMT Full Patent for Immunitor issued in China and EU Claims being re-filedNEW YORK, NY / ACCESSWIRE / February 18, 2021 / KEY CAPITAL CORPORATION (OTC PINK:KCPC) advises that it continues to work with Immunitor, its partner and Licensor, to progress ... Full Patent for Immunitor issued in China and EU Claims being re-filedNEW YORK, NY / ACCESSWIRE / February 18, 2021 / KEY CAPITAL CORPORATION (OTC PINK:KCPC) advises that it continues to work with...

Key Capital Corporation: Key Capital Strengthens Vaccine Patents Full Patent for Immunitor issued in China and EU Claims being re-filed NEW YORK, NY / ACCESSWIRE / February 18, 2021 / KEY CAPITAL CORPORATION (OTC PINK:KCPC) advises that it continues to work with Immunitor, its partner and Licensor, to progress further research and development of its breakthrough therapeutic vaccines, and for several unique supplements. PATENTS - Expanding Global Protection Key Capital, through its partnering and funding commitment with Immunitor recently finalized full patent filing in China, where local juri...

Key Capital Corporation: Key Capital to Distribute Novel Immune Supplement Promising Oral Pill Therapeutic Proposed to be Marketed as a Supplement NEW YORK, NY / ACCESSWIRE / January 28, 2021 / KEY CAPITAL CORPORATION (OTC Pink:KCPC) advises that as SARS-CoV-2 continues to spread, and reports of increases in daily infections, hospitalizations, and deaths are becoming regular, Key Capital plans to market its Immunitor partnered potentially therapeutic oral pill as a supplement commencing early February. Immunitor's proprietary and novel HapV+ ionic magnesium supplement, coupled with the patent...

Key Capital Corporation: Key Capital COVID-19 Oral Pill Vaccine Records 90% Reduction in Virus Infectivity in Early Study NEW YORK, NY / ACCESSWIRE / January 18, 2021 / KEY CAPITAL CORPORATION (OTC PINK:KCPC) is pleased to advise that current independent laboratory testing of its partnered Immunitor COVID-19 patented oral pill vaccine in an ongoing university study is providing promising early support for safety and efficacy of the vaccine. The preliminary tests conducted by a leading Asian research institute have shown safety and a 90% reduction on virus infectivity in mammalian cells follow...

Key Capital Corporation: Key Capital Advises Urgent Global Need For COVID-19 Oral Pill Therapeutic Vaccine advises that it is fast becoming clear that the approach to global COVID-19 vaccination is in crisis. While WHO advocates that: "no one is safe until everyone is safe", their COVAX facility viability is being questioned, with major cities and countries in various stages of lockdown, hospitals overwhelmed and sadly, as reported by the World Bank, this year will see COVID-19 responsible for as many as150 million people relegated to extreme poverty (living on less than US$1.90 / day). Milli...